期刊
EUROPEAN JOURNAL OF HAEMATOLOGY
卷 101, 期 3, 页码 305-317出版社
WILEY
DOI: 10.1111/ejh.13099
关键词
calreticulin; JAK2; myelofibrosis; myeloproliferative neoplasm; reduced intensity allogeneic stem cell transplantation; ruxolitinib
类别
资金
- Novartis
IntroductionRuxolitinib is the first approved drug for treatment of myelofibrosis, but its impact of outcome after allogeneic stem cell transplantation (ASCT) is unknown. Patients and methodsWe reported on 159 myelofibrosis patients (pts) with a median age of 59years (r: 28-74) who received reduced intensity ASCT between 2000 and 2015 in eight German centers from related (n=23), matched (n=86) or mismatched (n=50) unrelated donors. Forty-six (29%) patients received ruxolitinib at any time point prior to ASCT. The median daily dose of ruxolitinib was 30mg (range 10-40mg) and the median duration of treatment was 4.9months (range 0.4-39.1months). ResultsPrimary graft failure was seen in 2 pts (4%) in the ruxolitinib and 3 (2%) in the non-ruxolitinib group. Engraftment and incidence of acute GVHD grade II to IV and III/IV did not differ between groups (37% vs 39% and 19% vs 28%, respectively), nor did the non-relapse mortality at 2years (23% vs 23%). A trend for lower risk of relapse was seen in the ruxolitinib group (9% vs 17%, P=.2), resulting in a similar 2year DFS and OS (68% vs 60% and 73% vs 70%, respectively). No difference in any outcome variable could be seen between ruxolitinib responders and those who failed or lost response to ruxolitinib. ConclusionsThese results suggest that ruxolitinib pretreatment in myelofibrosis patient does not negatively influence outcome after allogeneic stem cell transplantation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据